{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.196.12.1516","meta":{"versionId":"6","lastUpdated":"2021-02-02T15:08:35.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2021-02-02"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1516","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.196.12.1516"}],"version":"20200310","name":"ErgoloidMesylates","title":"Ergoloid Mesylates","status":"active","experimental":false,"date":"2020-03-10T01:00:21-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for ergoloid mesylates.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use, prescribable ergoloid mesylates and ergoloid mesylates in combination with other medications.),(Exclusion Criteria: Excludes concepts that represent non-prescribable, branded drugs and excludes concepts that represent components or ingredients.)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1523"]}]},"expansion":{"identifier":"urn:uuid:cff499d3-f1ce-450d-ad68-57fad99270e0","timestamp":"2023-12-11T02:38:07-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"318179","display":"ergoloid mesylates, USP 1 MG Oral Tablet"}]}}